Hall et al. (2010) conducted a cross‐sectional analysis of the Myriad Genetics BRCA1/BRCA2 database and reported an overall 5.9% prevalence of BRCA1/BRCA2 mutations in non‐AJ patients with carcinoma in situ (CIS) (ductal or lobular). The gene discussed is BRCA2; the disease is in situ carcinoma.